These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36791564)

  • 1. XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma.
    Wang Z; Pan B; Yao Y; Qiu J; Zhang X; Wu X; Tang N
    Biomed Pharmacother; 2023 Apr; 160():114402. PubMed ID: 36791564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells.
    Sun J; Zheng X; Wang B; Cai Y; Zheng L; Hu L; Lu X; Xie S; Zhang X; Liu H; Ye L
    Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(2):261-270. PubMed ID: 35130616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
    Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
    Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
    Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
    Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
    Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
    Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
    Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXM1 augments sorafenib resistance and promotes progression of hepatocellular carcinoma by epigenetically activating KIF23 expression.
    Zhu C; Guo H; Ma Z; Shi S; Zhao X; Zhai D; Zhou X; Jiang P; Xu Q; Cai J
    Biochem Biophys Res Commun; 2023 May; 656():1-9. PubMed ID: 36940637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
    Tan W; Luo X; Li W; Zhong J; Cao J; Zhu S; Chen X; Zhou R; Shang C; Chen Y
    EBioMedicine; 2019 Feb; 40():446-456. PubMed ID: 30594557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
    Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
    J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.
    Xu Y; Xu H; Li M; Wu H; Guo Y; Chen J; Shan J; Chen X; Shen J; Ma Q; Liu J; Wang M; Zhao W; Hong J; Qi Y; Yao C; Zhang Q; Yang Z; Qian C; Li J
    Cancer Lett; 2019 Jul; 454():78-89. PubMed ID: 30980868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18.
    Gan H; Li L; Hu X; Cai J; Hu X; Zhang H; Zhao N; Xu X; Guo H; Pang P
    Cancer Biol Ther; 2022 Dec; 23(1):1-14. PubMed ID: 36310384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.
    Chen S; Du Y; Xu B; Li Q; Yang L; Jiang Z; Zeng Z; Chen L
    Oncogene; 2021 May; 40(19):3378-3393. PubMed ID: 33875785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.
    Chen J; Jiang S; Shao H; Li B; Ji T; Staiculescu D; He J; Zhao J; Cai L; Liang X; Xu J; Cai X
    Sci China Life Sci; 2022 Oct; 65(10):1998-2016. PubMed ID: 35380342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification.
    Kuang Y; Cheng Y; Wang J; Li H; Cao X; Wang Y
    Cancer Med; 2023 Mar; 12(6):7222-7233. PubMed ID: 36420693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
    Jin Y; Yang R; Ding J; Zhu F; Zhu C; Xu Q; Cai J
    Biochem Biophys Res Commun; 2021 Dec; 585():185-190. PubMed ID: 34808502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma.
    Pinato DJ; Brown MW; Trousil S; Aboagye EO; Beaumont J; Zhang H; Coley HM; Mauri FA; Sharma R
    Br J Cancer; 2019 Mar; 120(5):512-521. PubMed ID: 30765873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.